公开(公告)号：US20230144446A1

公开(公告)日：2023-05-11

申请号：US17814486

申请日：2022-07-22

申请人： Cassava Sciences, Inc.

发明人： Ian Pike ,  Michael Bremang ,  George Thornton

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/2821

摘要： The invention relates to sets of biomarkers and methods of use thereof for diagnosing, staging, treating, and assessing the response of a treatment for neurocognitive disorders characterised by tau toxicity, such as Alzheimer’s disease.

公开(公告)号：US20220233512A1

公开(公告)日：2022-07-28

申请号：US17517879

申请日：2021-11-03

申请人： Cassava Sciences, Inc.

发明人： Hoau-Yan Wang ,  Lindsay Burns Barbier

IPC分类号： A61K31/438 ,  A61K31/4709 ,  A61K31/4402 ,  A61P37/06 ,  A61P25/04 ,  A61K31/527

摘要： A method of inhibiting an immune response mediated by one or more of TLR2, RAGE, CCR5, CXR4 and CD4 cell surface receptors of cells in recognized need is disclosed. The method contemplates administering to such cells an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) whose structure is defined within. In one embodiment, the cells to which the compound or its salt is administered exhibit a hyperinflammatory syndrome.

公开(公告)号：US20240329056A1

公开(公告)日：2024-10-03

申请号：US18291014

申请日：2022-07-22

申请人： CASSAVA SCIENCES, INC.

发明人： Hoau-Yan WANG ,  George B. THORNTON

IPC分类号： G01N33/68

CPC分类号： G01N33/6896 ,  G01N2440/14 ,  G01N2800/2821 ,  G01N2800/52

摘要： A method of assaying for the presence of Alzheimer's disease (AD) in a living human subject using a serum or plasma sample preparation from that human subject is disclosed. In one aspect, the presence of an about 90 kDa filamin A (FLNA) polypeptide fragment in a sample preparation indicates that the sample donor likely had AD. More preferably, a ratio of the amount of that about 90 kDa FLNA polypeptide fragment to the amount of full length (about 280 kDa) FLNA protein in the sample preparation is determined. If that ratio is about 10 to about 2000, the donor likely had AD, whereas if that ratio is about 0.005 to about 5, the donor likely did not have AD. A method for determining the treatment prognosis of a living human subject presumed to have Alzheimer's disease (AD), a system and kit for carrying out the assays are also contemplated.

公开(公告)号：US20240117306A1

公开(公告)日：2024-04-11

申请号：US18323075

申请日：2023-05-24

申请人： CASSAVA SCIENCES, INC.

发明人： Hoau-Yan WANG ,  Lindsay BURNS BARBIER

IPC分类号： C12N5/079 ,  C07D205/04 ,  C07D207/08 ,  C07D211/14 ,  C07D211/74 ,  C07D217/04 ,  C07D265/30 ,  C07D265/36 ,  C07D277/02 ,  C07D277/04 ,  C07D279/12 ,  C07D295/08 ,  C07D295/088 ,  C07D471/10 ,  C07D491/04 ,  C07D491/056 ,  C07D498/10 ,  G01N33/50 ,  G01N33/68 ,  G01N33/94

CPC分类号： C12N5/0622 ,  C07D205/04 ,  C07D207/08 ,  C07D211/14 ,  C07D211/74 ,  C07D217/04 ,  C07D265/30 ,  C07D265/36 ,  C07D277/02 ,  C07D277/04 ,  C07D279/12 ,  C07D295/08 ,  C07D295/088 ,  C07D471/10 ,  C07D491/04 ,  C07D491/056 ,  C07D498/10 ,  G01N33/50 ,  G01N33/6896 ,  G01N33/94 ,  G01N2333/70571 ,  G01N2800/2821 ,  G01N2800/52

摘要： A method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system an effective amount of a of a compound or a pharmaceutically acceptable salt thereof that binds to a pentapeptide of filamin A (FLNA) of SEQ ID NO: 1, and contains at least four of the six pharmacophores of FIGS. 35-40.

公开(公告)号：US12065440B2

公开(公告)日：2024-08-20

申请号：US17850198

申请日：2022-06-27

申请人： Cassava Sciences, Inc.

发明人： Michael Zamloot ,  Lindsay Burns Barbier ,  Shawn Anthony Kucera

IPC分类号： C07D471/10

CPC分类号： C07D471/10 ,  C07B2200/13

摘要： The preparation and properties of crystalline polymorphs and solvates of 1-benzyl-8-methyl-1,4,8-triazaspiro-[4.5]-decan-2-one free base and of the mono- and dihydrochloride salts and solvates thereof are disclosed, as is an amorphous polymorph of the dihydrochloride. A pharmaceutical composition containing one or more polymorphs and a method of using that composition are also disclosed.

公开(公告)号：US20220340574A1

公开(公告)日：2022-10-27

申请号：US17850198

申请日：2022-06-27

申请人： Cassava Sciences, Inc.

发明人： Michael Zamloot ,  Lindsay Burns Barbier ,  Shawn Anthony Kucera

IPC分类号： C07D471/10

摘要： The preparation and properties of crystalline polymorphs and solvates of 1-benzyl-8-methyl-1,4,8-triazaspiro-[4.5]-decan-2-one free base and of the mono-and dihydrochloride salts and solvates thereof are disclosed, as is an amorphous polymorph of the dihydrochloride. A pharmaceutical composition containing one or more polymorphs and a method of using that composition are also disclosed.